Condition: Hypertriglyceridemia · Nonalcoholic Fatty Liver Disease · Sponsor: OrsoBio, Inc
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.
This description comes directly from the study's public registry record.
Ryan Huss, MD · 650-382-2225 · Clinicaltrials_Inquires@orsobio.com
Always discuss trial participation with your own doctor first.
| OrsoBio Research Site | Guadalajara, Jalisco, Mexico | Recruiting |
| OrsoBio Research Site | Zapopan, Jalisco, Mexico | Recruiting |
| OrsoBio Research Site | Mexico City, Mexico City, Mexico | Recruiting |
| OrsoBio Research Site | Mexico City, Mexico City, Mexico | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06564584